Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.470
+0.010 (0.68%)
At close: Jun 27, 2025, 4:00 PM
1.465
-0.005 (-0.34%)
After-hours: Jun 27, 2025, 4:00 PM EDT
Marker Therapeutics Revenue
Marker Therapeutics had revenue of $349.10K in the quarter ending March 31, 2025, a decrease of -71.94%. This brings the company's revenue in the last twelve months to $5.70M, up 71.53% year-over-year. In the year 2024, Marker Therapeutics had annual revenue of $6.59M with 99.06% growth.
Revenue (ttm)
$5.70M
Revenue Growth
+71.53%
P/S Ratio
2.46
Revenue / Employee
$1,139,225
Employees
5
Market Cap
16.63M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 6.59M | 3.28M | 99.06% |
Dec 31, 2023 | 3.31M | -202.41K | -5.76% |
Dec 31, 2022 | 3.51M | 2.27M | 182.96% |
Dec 31, 2021 | 1.24M | 774.93K | 166.01% |
Dec 31, 2020 | 466.79K | 253.59K | 118.95% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MRKR News
- 11 days ago - Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma - GlobeNewsWire
- 5 weeks ago - Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma - GlobeNewsWire
- 5 weeks ago - Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies - GlobeNewsWire
- 3 months ago - Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference - GlobeNewsWire
- 3 months ago - Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results - GlobeNewsWire
- 4 months ago - Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 6 months ago - Marker Therapeutics Announces $16.1 Million Private Placement - GlobeNewsWire
- 6 months ago - Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma - GlobeNewsWire